Cargando…

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades the low-density lipoprotein (LDL) receptor, leading to hypercholesterolemia and cardiovascular risk. Treatment with a statin leads to a compensatory increase in circulating PCSK9 level. Anagliptin, a dipeptidyl peptidase-4 (DPP-4) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8737073/ https://www.ncbi.nlm.nih.gov/pubmed/33342939 http://dx.doi.org/10.5551/jat.58396

Ejemplares similares

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication
por: Furuhashi, Masato, et al.
Publicado: (2022)

Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication
por: Furuhashi, Masato, et al.
Publicado: (2022)

Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals
por: Tanaka, Marenao, et al.
Publicado: (2022)

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria
por: Tanaka, Marenao, et al.
Publicado: (2020)

Differential regulation of hypoxanthine and xanthine by obesity in a general population
por: Furuhashi, Masato, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure
por: Yamaguchi, Satoshi, et al.
Publicado: (2019)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population
por: Higashiura, Yukimura, et al.
Publicado: (2022)

Independent links between plasma xanthine oxidoreductase activity and levels of adipokines
por: Furuhashi, Masato, et al.
Publicado: (2019)

Prognostic Impact of Early Changes in Serum Chloride Concentrations Among Hospitalized Acute Heart Failure Patients　― A Retrospective Cohort Study ―
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
por: Ikegami, Yuichi, et al.
Publicado: (2018)

Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials
por: Nezu, Uru, et al.
Publicado: (2013)

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
por: Xiao, Changting, et al.
Publicado: (2014)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

Low urine pH predicts new onset of diabetes mellitus during a 10‐year period in men: BOREAS‐DM1 study
por: Higashiura, Yukimura, et al.
Publicado: (2020)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
por: Nishio, Shinya, et al.
Publicado: (2015)

Antiatherosclerotic Phenotype of Perivascular Adipose Tissue Surrounding the Saphenous Vein in Coronary Artery Bypass Grafting
por: Mikami, Takuma, et al.
Publicado: (2021)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021)

Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
por: Kim, Sang-Yong, et al.
Publicado: (2022)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2021)

Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
por: Cheng, Sheng-Yao, et al.
Publicado: (2022)

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Chiba, Yukari, et al.
Publicado: (2018)

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury
por: Li, Qi, et al.
Publicado: (2017)

Epidemiology of adverse drug events and medication errors in four nursing homes in Japan: the Japan Adverse Drug Events (JADE) Study
por: Ayani, Nobutaka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hroit5d9l95rcit54n8mtm56tu